Literature DB >> 12945073

Randomized clinical trial of preoperative intranasal mupirocin to reduce surgical-site infection after digestive surgery.

Y Suzuki1, T Kamigaki, Y Fujino, M Tominaga, Y Ku, Y Kuroda.   

Abstract

BACKGROUND: Compromised patients subjected to major digestive surgery frequently develop infective complications caused by methicillin-resistant Staphylococcus aureus (MRSA), which may have dangerous consequences. This was a prospective randomized study to determine whether intranasal mupirocin could reduce postoperative infective complications in patients having digestive surgery.
METHODS: A total of 395 patients who underwent abdominal digestive surgery were assigned randomly into two groups: a treated group (193 patients) and controls (202). Patients in the treated group were given 30 mg mupirocin calcium hydrate ointment topically to each nostril three times a day on each of the 3 days before operation. The untreated group received no mupirocin treatment.
RESULTS: Most infections were due to Gram-negative bacteria in both groups. There were 21 Gram-positive infections detected at the surgical site, ten in the treated group and 11 in control patients. The incidence of pneumonia was significantly different between the groups (none in the treated group and five in control patients; P = 0.028). Four of five patients with pneumonia had a sputum culture containing MRSA.
CONCLUSION: Intranasal mupirocin treatment had no significant impact on surgical-site infection after digestive surgery. Copyright 2003 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12945073     DOI: 10.1002/bjs.4269

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  8 in total

Review 1.  Pre-surgical Nasal Decolonization of Staphylococcus aureus: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2022-08-23

2.  A preoperative decolonization protocol for staphylococcus aureus prevents orthopaedic infections.

Authors:  Nalini Rao; Barbara Cannella; Lawrence S Crossett; A J Yates; Richard McGough
Journal:  Clin Orthop Relat Res       Date:  2008-04-11       Impact factor: 4.176

3.  Protecting patients from infection: Improving topical prophylaxis compliance on surgical wards.

Authors:  Holly Slyne; Natalie Clews; Sid Beech; Elizabeth Smilie
Journal:  J Infect Prev       Date:  2019-11-26

4.  The Japan Society for Surgical Infection: guidelines for the prevention, detection, and management of gastroenterological surgical site infection, 2018.

Authors:  Hiroki Ohge; Toshihiko Mayumi; Seiji Haji; Yuichi Kitagawa; Masahiro Kobayashi; Motomu Kobayashi; Toru Mizuguchi; Yasuhiko Mohri; Fumie Sakamoto; Junzo Shimizu; Katsunori Suzuki; Motoi Uchino; Chizuru Yamashita; Masahiro Yoshida; Koichi Hirata; Yoshinobu Sumiyama; Shinya Kusachi
Journal:  Surg Today       Date:  2020-12-15       Impact factor: 2.549

Review 5.  Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors.

Authors:  Seung-Hyun Jeong; Ji-Hun Jang; Yong-Bok Lee
Journal:  J Pharm Investig       Date:  2022-07-24

6.  Management of post-surgical infection of onychocryptosis with topical application of hyaluronic acid versus antibacterial ointments.

Authors:  Almudena Núñez Fernández; Alvaro Gómez-Carrión; Ignacio Zaragoza-García; Carlos Martínez Sebastián; Paola Sanz Wozniak; Arturo Gómez Lara; Arturo Saura-Sempere; Rubén Sánchez-Gómez
Journal:  Heliyon       Date:  2022-08-08

Review 7.  Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers.

Authors:  Miranda van Rijen; Marc Bonten; Richard Wenzel; Jan Kluytmans
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

Review 8.  Antimicrobial approaches in the prevention of Staphylococcus aureus infections: a review.

Authors:  D P R Troeman; D Van Hout; J A J W Kluytmans
Journal:  J Antimicrob Chemother       Date:  2019-02-01       Impact factor: 5.790

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.